From MarketBeat:

Kamada Ltd. (NASDAQ:KMDA) saw a 730.7% increase in short interest in December, with 62,300 shares sold short, 0.2% of the company. Based on an average daily volume of 64,900 shares, the short-interest ratio is 1.0 days.

HC Wainwright reiterated a “buy” rating on KMDA, while StockNews.com lowered it to “hold”. Most recently, KMDA was given a $11.00 target price and a “buy” rating.

Hedge funds like Vanguard Group Inc., Renaissance Technologies LLC, and Wells Fargo & Company MN have modified their holdings of KMDA. A significant portion of the company’s stock is owned by institutional investors and hedge funds.

NASDAQ KMDA traded down to $6.20 with a market capitalization of $277.88 million. Its 50-day moving average is $5.02 and its two-hundred day moving average is $5.16.

Kamada released its quarterly earnings results on Monday, November 13th and reported $0.06 earnings per share, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $37.93 million during the quarter.

Kamada Ltd. provides plasma-derived protein therapeutics and operates in two segments, Proprietary Products and Distribution. It offers products for various medical conditions and needs.

This news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with fast and accurate reporting. No promotion of services was included in the article.



Read more: Kamada Ltd. (NASDAQ:KMDA) Short Interest Update